# 4965
Last night Robert Roos, news editor for CIDRAP, wrote a long and informative article on the results of a new study on cell-based vaccine production.
As an added bonus, you’ll find extended and insightful comments from CIDRAP’s director, Dr. Michael Osterholm.
Although hailed by proponents as the future of vaccine production, cell-based vaccines still have obstacles ahead. And as Dr. Osterholm points out, cell-based vaccine production may provide only an incremental improvement over egg-based technology.
Follow the link, this report is well worth reading it its entirety.
Trial answers some, not all, questions on cell-based flu vaccines
Robert Roos
News Editor
Oct 6, 2010 (CIDRAP News) – A new report says that a cell culture derived influenza vaccine and a conventional egg-based vaccine both proved effective in a large international clinical trial, offering support for those who contend that cell-based vaccines should become an important part of flu vaccine supplies in coming years.
But it remains to be seen whether cell culture production, which has been discussed for years, is the wave of the future for flu vaccines. Some doubts persist as to whether it offers sufficient advantages in effectiveness and production time to replace the traditional egg-based technology.
